Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Retained Earnings (2023 - 2025)

Kura Oncology (KURA) has disclosed Retained Earnings for 3 consecutive years, with -$1.2 billion as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 31.12% to -$1.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.2 billion, a 31.12% decrease, with the full-year FY2025 number at -$1.2 billion, down 31.12% from a year prior.
  • Retained Earnings was -$1.2 billion for Q4 2025 at Kura Oncology, down from -$1.1 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $1.1 million in Q3 2024 to a low of -$1.2 billion in Q4 2025.
  • A 3-year average of -$506.5 million and a median of -$659.4 million in 2023 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: skyrocketed 100.16% in 2024, then plummeted 98047.04% in 2025.
  • Kura Oncology's Retained Earnings stood at -$1.3 million in 2023, then crashed by 70350.2% to -$895.4 million in 2024, then tumbled by 31.12% to -$1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for KURA's Retained Earnings are -$1.2 billion (Q4 2025), -$1.1 billion (Q3 2025), and $711000.0 (Q2 2025).